Roche underlines obesity and Alzheimer’s ambitions
Swiss pharma giant Roche (ROG: SIX) could be among the best-placed drugmakers to tackle two of today’s biggest challenges in global healthcare, according to Teresa Graham, chief executive of its Pharmaceuticals division.
Speaking at The Financial Times’ Global Pharma and Biotech Summit in London, UK, this week, Ms Graham outlined the potential that her company has to treat patients with obesity and Alzheimer’s, diseases which represent two of the largest market opportunities for those that offer effective solutions.
In obesity, while Roche has found itself behind early frontrunners Novo Nordisk (NOV: N) and Eli Lilly (NYSE: LLY), but Ms Graham is very confident in the portfolio of treatments that the company is developing, which includes both injectable and oral medications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze